Ann Surg Oncol

1. HU Z, Gu X, Fu H
   Beyond Uptake: Aligning Low-Dose Tamoxifen Adherence with Absolute Breast Cancer Risk.
   Ann Surg Oncol. 2026 Mar 30. doi: 10.1245/s10434-026-19521.
   

   >> Share

   
   
2. SHERN TP, Holt LR, Lloyd K, Daly AE, et al
   Economic and Health System Impact of Implementing the SOUND Trial Approach in Early-Stage Breast Cancer.
   Ann Surg Oncol. 2026 Mar 30. doi: 10.1245/s10434-026-19564.
   

   >> Share

   
   
3. GALLAGHER K, Feldman S, Barone J, Mammen J, et al
   ASO Visual Abstract: Prospective Phase II Multicenter Trial of Ablation after Breast Lumpectomy Added To Extend (ABLATE) Intraoperative Margins for the Sole Local Treatment of Breast Cancer.
   Ann Surg Oncol. 2026 Mar 30. doi: 10.1245/s10434-026-19402.
   

   >> Share

   
   
4. GRAHAM-STEPHENSON A, Fanning CE, Geven EL, Migyanka F, et al
   Geographic Differences in Patient Experience After a Diagnosis of Lobular Breast Cancer.
   Ann Surg Oncol. 2026 Mar 31. doi: 10.1245/s10434-026-19523.
   

   >> Share

   
   
5. JUNG JJ, Kim HK, Kang E, Park EK, et al
   ASO Visual Abstract: Enhancing Early Detection of Contralateral Breast Cancer in Breast Cancer Survivors Using AI-Assisted Mammography.
   Ann Surg Oncol. 2026 Apr 2. doi: 10.1245/s10434-026-19535.
   

   >> Share

   
   
6. ABDULLA HA, McGarry J, Prichard RS, Boland MR, et al
   Reply to: "Letter to the Editor Regarding Abdulla HA, McGarry J, Kaczorowska R, et al. Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Syst
   Ann Surg Oncol. 2026 Apr 3. doi: 10.1245/s10434-026-19615.
   

   >> Share

   
   
7. STONEBANKS CUILLERIER NJ, Wong SM
   Reply to "Beyond Uptake Aligning Low-Dose Tamoxifen Adherence with Absolute Breast Cancer Risk," by Hu, Zhiping et al.
   Ann Surg Oncol. 2026 Apr 2. doi: 10.1245/s10434-026-19525.
   

   >> Share

   
   

   
   BMC Cancer

8. HUANG Z, Muritti C, Sieuwerts A, de Weerd V, et al
   Interrelation between lncRNA HOTAIR and EZH2 expression and progression free survival during endocrine treatment in breast cancer.
   BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15876.
   

   >> Share

   
   
9. HU J, Xiong Z, Wang X
   Prognostic value of pre-treatment serum CA19-9 and lymphocyte-to-monocyte ratio in HR+/HER2- breast cancer: a retrospective cohort study.
   BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15941.
   

   >> Share

   
   
10. XU H, Wang Y, Sa Q, Zhou Y, et al
    Treatment for metastatic triple-negative breast cancer with homologous recombination deficiency: a Bayesian network meta-analysis.
    BMC Cancer. 2026 Apr 2. doi: 10.1186/s12885-026-15947.
    

    >> Share

    
    

    
    Br J Cancer

11. KOKTS-PORIETIS RL, Morielli AR, Yang L, Matthews CE, et al
    Associations of health-related fitness and physical activity with chemotherapy outcomes in breast cancer.
    Br J Cancer. 2026 Mar 27. doi: 10.1038/s41416-026-03384.
    

    >> Share

    
    
12. MAVADDAT N, Barnes DR, Michailidou K, Zhao E, et al
    Natural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis.
    Br J Cancer. 2026 Mar 30. doi: 10.1038/s41416-026-03365.
    

    >> Share

    
    
13. ANDERSON J, Lawton S, Thackray K, Kipps E, et al
    Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer-comparing real-world outcomes in England to the MONARCH-2 trial.
    Br J Cancer. 2026 Mar 30. doi: 10.1038/s41416-026-03396.
    

    >> Share

    
    

    
    Breast Cancer

14. KATO C, Sota Y, Kitano S, Watanabe A, et al
    Integration of gene expression profiling and mutation analysis via RNA sequencing: transitioning the 95-gene classifier to a next-generation platform in early-stage HR+/HER2- breast cancer.
    Breast Cancer. 2026 Apr 1. doi: 10.1007/s12282-026-01854.
    

    >> Share

    
    
15. GUI Z, Zhao L, Liu S, Zhang L, et al
    Solamargin-functionalized gold nanoparticles codelivering photothermal-immunotherapy for triple-negative breast cancer.
    Breast Cancer. 2026 Apr 1. doi: 10.1007/s12282-026-01849.
    

    >> Share

    
    
16. AOYAMA Y, Kashiwabara K, Kikawa Y, Taira N, et al
    Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial.
    Breast Cancer. 2026 Mar 30. doi: 10.1007/s12282-026-01852.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

17. LI H, Li X, Tang S
    Clinical Value of Cardiac Troponin I in Assessing Anthracycline-Induced Cardiotoxicity in Postoperative Breast Cancer Patients.
    Breast Cancer (Dove Med Press). 2026;18:580515.
    

    >> Share

    
    
18. HE L, Zhang W, Huang L, Lin X, et al
    A Retrospective Analysis of a Serum Multi-Biomarker (CA153, TSGF, and CYFRA 21-1) Logistic Regression Model for Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:567301.
    

    >> Share

    
    
19. LI D, Zhang Z, Chen Y, Zhao X, et al
    Identification of circRNA/lncRNA-miRNA-Transcription Factor-mRNA Networks to Identify Potential Biomarkers in Response to Neoadjuvant Therapy for Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:538948.
    

    >> Share

    
    
20. DIRIE AM, Ahmed NR, Dirie SA, Hassan SA, et al
    Health Related Quality of Life Among Women with Breast Cancer in Mogadishu, Somalia.
    Breast Cancer (Dove Med Press). 2026;18:587275.
    

    >> Share

    
    
21. LI S, Li R, Xu M, Liao J, et al
    Deep Learning Radiomics of Multiparametric MRI for Individualized Prediction of Axillary Lymph Node Response After Neoadjuvant Chemotherapy in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:568337.
    

    >> Share

    
    

    
    Breast Cancer Res

22. MELLOR P, Smith SE, Kendall S, Kyrylenko L, et al
    CLIC3 is upregulated across all subtypes of breast cancer and plays a key role in cell migration, invasion and growth in soft agar.
    Breast Cancer Res. 2026 Apr 3. doi: 10.1186/s13058-026-02270.
    

    >> Share

    
    
23. ABE JV, Fukui J, Wilkens LR, Cheng I, et al
    Risk factors for ductal carcinoma in situ: comparisons with invasive breast cancer.
    Breast Cancer Res. 2026 Apr 1. doi: 10.1186/s13058-026-02266.
    

    >> Share

    
    
24. DENG R, Ren Y, Hu K, Zhang Y, et al
    Integrated multi-omics analysis and functional validation reveal the role of TRIM2 as a potential novel biomarker in breast cancer.
    Breast Cancer Res. 2026 Mar 31. doi: 10.1186/s13058-026-02263.
    

    >> Share

    
    
25. TANG L
    Single-cell landscape of intratumoral heterogeneity and GABA-mediated remodeling of the immune microenvironment in breast cancer metastases.
    Breast Cancer Res. 2026 Mar 31. doi: 10.1186/s13058-026-02268.
    

    >> Share

    
    
26. LUNDGREN C, Frediksson I, Valachis A, Smith DR, et al
    PREDICT v3.0 outperforms v2.2 in young (25-40 years) breast cancer patients according to real-world data from a large Swedish population-based registry.
    Breast Cancer Res. 2026 Mar 31. doi: 10.1186/s13058-026-02271.
    

    >> Share

    
    
27. GAO Y, Xu M, Zhang M, Sun G, et al
    Development and validation of an online prognostic risk stratification tool to assist decisions on perioperative chemotherapy for men with luminal early breast cancer.
    Breast Cancer Res. 2026 Mar 28. doi: 10.1186/s13058-026-02252.
    

    >> Share

    
    
28. CHEN L, Kong L, Yang J, Xue J, et al
    [(68)Ga]Ga-labeled fibroblast activation protein inhibitor PET/CT for monitoring neoadjuvant chemotherapy responses in breast cancer subtypes.
    Breast Cancer Res. 2026 Mar 28. doi: 10.1186/s13058-026-02267.
    

    >> Share

    
    
29. ANNIBALINI G, Sisti D, De Santi M, Natalucci V, et al
    Lifestyle intervention based on aerobic exercise and Mediterranean diet modulates IGF-1 and its binding proteins in breast cancer survivors.
    Breast Cancer Res. 2026 Mar 27. doi: 10.1186/s13058-026-02262.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

30. CHIDDARWAR T, Blaes A, Kuntz K
    Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.
    Breast Cancer Res Treat. 2026;217:2.
    

    >> Share

    
    
31. MITSUEDA R, Sagara Y, Niikura N, Ohno S, et al
    Real-world treatment patterns and outcomes in older patients with metastatic breast cancer: a multi-institutional retrospective cohort study.
    Breast Cancer Res Treat. 2026;217:3.
    

    >> Share

    
    
32. TAVARES GM, Ramalho SOB, da Silva LR, Telles GD, et al
    Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2026;217:4.
    

    >> Share

    
    
33. RUGO HS, Pluard TJ, Sharma P, Melisko M, et al
    OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.
    Breast Cancer Res Treat. 2026;217:5.
    

    >> Share

    
    
34. KUPIS W, Klosowska D, Harhala M, Sekula M, et al
    The use of endpoints in phase 3 randomized controlled trials in metastatic breast cancer.
    Breast Cancer Res Treat. 2026;217:6.
    

    >> Share

    
    
35. DECKER KM, Feely A, Pitz M, Hebbard P, et al
    The impact of the COVID-19 pandemic on breast cancer screening, treatment, and overall survival.
    Breast Cancer Res Treat. 2026;217:7.
    

    >> Share

    
    
36. MOLNAR AO, McArthur E, Bota SE, Stirling K, et al
    Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study.
    Breast Cancer Res Treat. 2026;217:10.
    

    >> Share

    
    
37. LOPEZ JCV, Ho A, Hughes KS, Bardia A, et al
    Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence.
    Breast Cancer Res Treat. 2026;217:8.
    

    >> Share

    
    
38. HORNER M, Tretschock LM, John N, Ziegler P, et al
    Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.
    Breast Cancer Res Treat. 2026;217:9.
    

    >> Share

    
    

    
    Breast J

39. MATH P, Sajith G, Mahadevappa K, Hegde SG, et al
    Defining Multiple Fibroadenomas: A Systematic Review of Clinical Characteristics and Management.
    Breast J. 2026;2026:e5572826.
    

    >> Share

    
    
40. JAVED SR, DeSouza K, Tanzim U, Ottaviani D, et al
    A Five-Year Retrospective Analysis of Neoadjuvant Therapy in Early-Stage Breast Cancer: Subtype Outcomes and Imaging Concordance.
    Breast J. 2026;2026:e9197063.
    

    >> Share

    
    
41. SU J, Lee YY, Kao WB, Abdul Rauf NH, et al
    "Going Flat" in Nipple-Sparing Mastectomy-An Analysis of Patient-Reported Outcome Measurements of Preliminary 57 Procedures.
    Breast J. 2026;2026:e5032690.
    

    >> Share

    
    

    
    Cancer

42. CHEN I
    Design-analysis mismatch in the analysis of longitudinal HER2 data in breast cancer.
    Cancer. 2026;132:e70383.
    

    >> Share

    
    
43. FU F
    Reply to "Design-analysis mismatch in the analysis of longitudinal HER2 data in breast cancer".
    Cancer. 2026;132:e70385.
    

    >> Share

    
    
44. CASWELL-JIN JL, Dickerson JC, Kurian AW
    Guideline concordance in triple-negative breast cancer: What does it measure?
    Cancer. 2026;132:e70381.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

45. YUK JS, Kim BS, Kim BY, Park JY, et al
    Association between Menopausal Hormone Therapy and Cancer: A Nationwide Retrospective Cohort Study in South Korea.
    Cancer Epidemiol Biomarkers Prev. 2026;35:569-577.
    

    >> Share

    
    

    
    Cancer Lett

46. GHOSH D, White B, Lu X, Perricone M, et al
    Autophagy is essential for survival and function of polyploid giant cancer cells under therapeutic stress.
    Cancer Lett. 2026;646:218431.
    

    >> Share

    
    

    
    Cancer Res

47. TANKKA AT, Zhang Y, Einstein JM, Zhou CJ, et al
    Integrative CRISPR Screening and RNA Analyses Discover an Essential Role for PUF60 Interactions with 3' Splice Sites in Cancer Progression.
    Cancer Res. 2026;86:1586-1604.
    

    >> Share

    
    

    
    Cell

48. CAIRE R, Bordo R, Zanconato F, Panciera T, et al
    A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer.
    Cell. 2026 Mar 31:S0092-8674(26)00276-X. doi: 10.1016/j.cell.2026.
    

    >> Share

    
    

    
    Clin Breast Cancer

49. TENREIRO A, Sun J, Whitman G, Dinh A, et al
    Locoregional Nodal Status at Initial Presentation on Ultrasound (US) and Positron Emission Tomography/Computerized Tomography ((18)F-FDG PET/CT) in Inflammatory Breast Cancer (IBC) Patients is Predictive of Overall Survival.
    Clin Breast Cancer. 2026;26:109-118.
    

    >> Share

    
    
50. ZHANG Z, Ma X, Zhang J, Zhao Y, et al
    The Role of Primary Tumor Surgery in Oligometastatic Breast Cancer: A Meta-Analysis of Randomized and Observational Studies.
    Clin Breast Cancer. 2026;26:1-10.
    

    >> Share

    
    
51. CARVALHO GS, Rodrigues FR, Fernandes PV, Small IA, et al
    Real-World Evidence of Immunohistochemical Discordance in Breast Cancer Brain Metastases.
    Clin Breast Cancer. 2026 Mar 7:S1526-8209(26)00034.
    

    >> Share

    
    
52. CESCON E, Goodwin P, Bobrie A, Thezenas S, et al
    Plasma Hepcidin as a Prognostic Biomarker in Obese and Nonobese Patients With Early Breast Cancer: A Pooled Analysis of Two Prospective Cohort Studies.
    Clin Breast Cancer. 2026;26:29-35.
    

    >> Share

    
    

    
    Clin Cancer Res

53. POISSONNIER A, Rugo HS, Horton W, Kim T, et al
    CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.
    Clin Cancer Res. 2026 Mar 27. doi: 10.1158/1078-0432.CCR-25-4236.
    

    >> Share

    
    
54. BHARADWAJ S, Corredor G, Al-Shakhshir H, Medina S, et al
    Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation.
    Clin Cancer Res. 2026 Mar 31. doi: 10.1158/1078-0432.CCR-25-4185.
    

    >> Share

    
    

    
    Eur J Cancer

55. SCAFETTA R, Troiano R, Gullotta C, Guarino A, et al
    Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+?/HER2?- breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.
    Eur J Cancer. 2026;239:116703.
    

    >> Share

    
    

    
    Eur J Surg Oncol

56. RYU JM, Lee HB, Han W, Chung IY, et al
    Clinicopathologic characteristics and lymph node status in the NAUTILUS clinical trial:KBCSG-21.
    Eur J Surg Oncol. 2026;52:111458.
    

    >> Share

    
    
57. LATIF A, Al Janabi N, Joshi M, Che Bakri NA, et al
    Feedback from wearable devices accelerates recovery after breast cancer surgery.
    Eur J Surg Oncol. 2026;52:111784.
    

    >> Share

    
    

    
    Eur Radiol

58. VAN AMSTEL FJG, van Mierlo RGM, Nelemans PJ, Engelen SME, et al
    Publisher Correction: Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy.
    Eur Radiol. 2026 Apr 2. doi: 10.1007/s00330-026-12508.
    

    >> Share

    
    
59. XIE H, Wang X, Guo W, Wu Y, et al
    Prediction model to prevent axillary surgery using axillary US and MRI in early breast cancer.
    Eur Radiol. 2026 Apr 2. doi: 10.1007/s00330-026-12494.
    

    >> Share

    
    

    
    Exp Cell Res

60. SONG H, Li H, Bian Y, Song J, et al
    AGTPBP1 promotes breast cancer progression via the EVPL/ERK signaling axis.
    Exp Cell Res. 2026;458:115001.
    

    >> Share

    
    

    
    Int J Cancer

61. NAM SY, Jo J
    The effect of body mass index change on breast and uterine cancer risk in middle- and older-aged adults.
    Int J Cancer. 2026 Jan 2. doi: 10.1002/ijc.70325.
    

    >> Share

    
    

    
    Int J Oncol

62. GONDI CS, Gorantla B, Rao AKSB, Amala K, et al
    [Retracted] Antitumor activity of NRC?AN?019 in a pre?clinical breast cancer model.
    Int J Oncol. 2026;68:66.
    

    >> Share

    
    
63. LI Q, Jiang M, Zhu B, Wei W, et al
    Hypoxia?induced exosomal CAMTA1 promotes radio?resistance in MDA?MB?231 cells by regulating NRG1 to mediate M2 macrophage polarization.
    Int J Oncol. 2026;68:62.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

64. ROSENZWEIG SJ, Boe LA, Wen HY, Mueller B, et al
    Molecular risk stratification for decision-making among patients with breast cancer eligible to omit radiotherapy.
    Int J Radiat Oncol Biol Phys. 2026 Mar 25:S0360-3016(26)00517.
    

    >> Share

    
    

    
    J Clin Oncol

65. GANDHI A, Howell SJ, Harkness EF, Woodward E, et al
    Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers.
    J Clin Oncol. 2026;44:874-882.
    

    >> Share

    
    
66. BOSSERMAN LD, Dizon DS
    Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition.
    J Clin Oncol. 2026 Mar 31:JCO2503121. doi: 10.1200/JCO-25-03121.
    

    >> Share

    
    

    
    J Natl Cancer Inst

67. NG DQ, Heshmatipour M, Trudeau J, Sridhar A, et al
    Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.
    J Natl Cancer Inst. 2026 Apr 2:djag096. doi: 10.1093.
    

    >> Share

    
    

    
    J Nucl Med

68. COLD S, Sadasivam P, Wessel MM, Ischyropoulou M, et al
    In Vivo Studies of [(161)Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2-Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression.
    J Nucl Med. 2026 Feb 12:jnumed.125.269741. doi: 10.2967/jnumed.125.269741.
    

    >> Share

    
    

    
    N Engl J Med

69. 
    Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
    N Engl J Med. 2026;394:1352.
    

    >> Share

    
    

    
    NPJ Breast Cancer

70. WANG L, Wan Z, Dhillon V, Wang X, et al
    Disparities in breast cancer incidence and survival by age, race, and molecular subtype in US women.
    NPJ Breast Cancer. 2026 Mar 27. doi: 10.1038/s41523-026-00935.
    

    >> Share

    
    
71. RENTZ LE, Dierkes MK, Vettiyil B, Holaskova I, et al
    Characterization of body composition dynamics throughout treatment in patients with early-stage breast cancer.
    NPJ Breast Cancer. 2026 Mar 28. doi: 10.1038/s41523-026-00933.
    

    >> Share

    
    
72. SHI W, Pan Y, Rathod B, Wang Y, et al
    TGF-alpha/EGFR-mediated lymphatic metastasis reveals a repositionable therapeutic target in breast cancer.
    NPJ Breast Cancer. 2026 Apr 3. doi: 10.1038/s41523-026-00941.
    

    >> Share

    
    

    
    Oncogene

73. GADAD SS, Camacho CV, Gong X, Thornton M, et al
    X-linked cancer-associated polypeptide (XCP) from lncRNA1456 modulates PHF8 histone demethylase activity to regulate the epigenome, gene expression, and cellular pathways in breast cancer.
    Oncogene. 2026 Apr 1. doi: 10.1038/s41388-026-03740.
    

    >> Share

    
    

    
    Oncology

74. ALFAYA L, Camacho X, Cabrera M, Tassano M, et al
    Preclinical Evaluation of (99m)Tc-Labeled LHRH Analog as Cancer Receptor Imaging.
    Oncology. 2026;104:381-393.
    

    >> Share

    
    

    
    Oncology (Williston Park)

75. ZEBING LUO MSN, Manjia Xu Bns, Shuxian Yu Bns, Weijie Gao Bns, et al
    Exploring the Influencing Factors of Quality of Life During Maintenance Phase in Patients With Breast Cancer-Related Lymphedema.
    Oncology (Williston Park). 2026;40:115-122.
    

    >> Share

    
    
76. MANJINDER SINGH SIDHU MD, Deepak Abrol Md, Mohan Lal Md, Sumeet Aggarwal Md, et al
    A Multicenter Quality Audit Standardizing Esophageal Contouring in Postmastectomy Radiotherapy.
    Oncology (Williston Park). 2026;40:10-14.
    

    >> Share

    
    

    
    PLoS Comput Biol

77. SU JC, Lee CL, Yang FW, Chen YC, et al
    Network-based exploration of 4-(phenylsulfonyl)morpholine molecules for metastatic triple-negative breast cancer suppression.
    PLoS Comput Biol. 2026;22:e1014132.
    

    >> Share

    
    

    
    PLoS One

78. LI Y, Chong M, Chui P, Mo L, et al
    Navigating parenting challenges: A qualitative study of communication experiences among young Chinese couples facing breast cancer while raising underage children.
    PLoS One. 2026;21:e0345543.
    

    >> Share

    
    
79. CHIANG PY, Huang PJ, Hung CH, Lin CP, et al
    Deep inspiration breath hold versus free breathing in postoperative radiotherapy strategy for patients with left-sided breast cancer treated with volumetric modulated arc therapy: A meta-analysis and systematic review.
    PLoS One. 2026;21:e0345614.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

80. LI Z, Wang Y, Chen Z, Liu R, et al
    WFDC21P is essential for G3BP1-mediated RIG-I activation and antitumor immunity in triple-negative breast cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2532576123.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

81. COZZI A
    AI and Breast Cancer Screening at a Crossroads: Insights from the MASAI Trial.
    Radiol Imaging Cancer. 2026;8:e269007.
    

    >> Share

    
    

    
    Radiother Oncol

82. CANHA-BORGES A, Nunes B, Estevao D, Fernandes R, et al
    Radiotherapy induces layer-specific molecular and ultrastructural alterations in triple-negative breast cancer spheroids.
    Radiother Oncol. 2026 Mar 30:111518. doi: 10.1016/j.radonc.2026.111518.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share